Matthew 25 Management Corp Purchases 8,250 Shares of Eli Lilly and Company $LLY

Key Points

• Matthew 25 Management Corp more than doubled its stake in Eli Lilly, buying an additional 8,250 shares in Q3 to own 15,500 shares (a 113.8% increase), holdings valued at about $11.83 million and representing ~3.6% of the fund's portfolio.
• Eli Lilly beat Q4 estimates (EPS $7.54 vs. $7.48; revenue $19.29B vs. $17.85B), with revenue up 42.6% year‑over‑year and FY2026 guidance set at $33.50–$35.00 EPS, supporting continued growth expectations.
• Dividend lift and positive analyst bias: Lilly raised its quarterly dividend to $1.73 ($6.92 annualized, ~0.7% yield), and analysts maintain a generally bullish stance (consensus rating "Moderate Buy" with an average target ~ $1,229.59 and several firms raising targets).

Matthew 25 Management Corp boosted its position in Eli Lilly and Company (NYSE:LLY - Free Report) by 113.8% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,500 shares of the company's stock after buying an additional 8,250 shares during the quarter. Eli Lilly and Company makes up about 3.6% of Matthew 25 Management Corp's holdings, making the stock its 13th biggest position. Matthew 25 Management Corp's holdings in Eli Lilly and Company were worth $11,826,000 at the end of the most recent reporting period.

Other institutional investors have also recently bought and sold shares of the company. Sumitomo Mitsui Financial Group Inc. bought a new stake in Eli Lilly and Company during the second quarter valued at about $27,000. Evolution Wealth Management Inc. bought a new position in shares of Eli Lilly and Company in the second quarter worth about $29,000. Steph & Co. lifted its position in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph & Co. now owns 39 shares of the company's stock worth $30,000 after purchasing an additional 29 shares during the last quarter. Financial Gravity Companies Inc. acquired a new position in shares of Eli Lilly and Company during the 2nd quarter worth about $31,000. Finally, Bare Financial Services Inc boosted its stake in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company's stock valued at $31,000 after purchasing an additional 29 shares during the period. Institutional investors own 82.53% of the company's stock.

Eli Lilly and Company Trading Up 0.7%

Shares of LLY stock opened at $990.58 on Friday. The company has a market capitalization of $934.47 billion, a P/E ratio of 43.16, a P/E/G ratio of 1.15 and a beta of 0.40. Eli Lilly and Company has a 12-month low of $623.78 and a 12-month high of $1,133.95. The company has a quick ratio of 1.19, a current ratio of 1.58 and a debt-to-equity ratio of 1.54. The firm has a 50-day moving average price of $1,045.63 and a 200 day moving average price of $940.90.

Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings data on Wednesday, February 4th. The company reported $7.54 earnings per share for the quarter, topping the consensus estimate of $7.48 by $0.06. The firm had revenue of $19.29 billion for the quarter, compared to analysts' expectations of $17.85 billion. Eli Lilly and Company had a net margin of 31.66% and a return on equity of 102.94%. The company's quarterly revenue was up 42.6% compared to the same quarter last year. During the same period in the prior year, the firm earned $5.32 earnings per share. Eli Lilly and Company has set its FY 2026 guidance at 33.500-35.000 EPS. Research analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Investors of record on Friday, February 13th will be given a dividend of $1.73 per share. This is a boost from Eli Lilly and Company's previous quarterly dividend of $1.50. The ex-dividend date is Friday, February 13th. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company's dividend payout ratio is currently 30.15%.

Analyst Ratings Changes

A number of analysts have issued reports on the company. Guggenheim raised their target price on Eli Lilly and Company from $1,161.00 to $1,168.00 and gave the company a "buy" rating in a report on Thursday, February 26th. Wells Fargo & Company upped their price target on Eli Lilly and Company from $1,200.00 to $1,280.00 and gave the stock an "overweight" rating in a report on Thursday, February 5th. National Bank Financial set a $1,286.00 price objective on Eli Lilly and Company in a research report on Monday, December 1st. Barclays began coverage on shares of Eli Lilly and Company in a research note on Thursday, February 19th. They issued an "overweight" rating and a $1,350.00 price objective on the stock. Finally, Deutsche Bank Aktiengesellschaft reiterated a "buy" rating and set a $1,285.00 target price on shares of Eli Lilly and Company in a research note on Friday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and five have issued a Hold rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $1,229.59.

Key Stories Impacting Eli Lilly and Company

Here are the key news stories impacting Eli Lilly and Company this week:

• Positive Sentiment: Lilly launched "Lilly Employer Connect," a direct-to-employer platform designed to broaden employer coverage of its obesity medicines (Zepbound/tirzepatide), which could increase uptake and stabilize pricing dynamics by offering predictable pricing for employers. Lilly Employer Connect platform launches
• Positive Sentiment: GoodRx expanded employer-sponsored access to Zepbound KwikPen, offering a set price across doses — a commercial channel that can boost volume and lower friction for adoption among employees. GoodRx to Expand Employer-Sponsored Access to Zepbound® KwikPen®
• Positive Sentiment: Pipeline and clinical updates: completion/updates on the TRANSCEND‑T2D‑1 trial for retatrutide and progress in abemaciclib combos deepen Lilly’s obesity and oncology optionality — news that supports longer‑term growth expectations. TRANSCEND-T2D-1 Trial Completion
• Positive Sentiment: Analyst support: UBS and other analysts emphasize Lilly’s leadership in next‑generation obesity therapies and maintained/installed Buy views, which underpins demand for the stock. Analyst Buy Rating on Lilly
• Neutral Sentiment: Industry context: competitor data (Roche/Zealand) showed mixed results — some rivals lag GLP‑1 leaders — which can modestly benefit market share expectations for Lilly but is not a direct near‑term driver. Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants
• Neutral Sentiment: Broader coverage and media analysis ask whether LLY’s high absolute share price leaves room to run — useful for positioning but not an immediate catalyst absent valuation or guidance changes. Is It Too Late To Consider Eli Lilly (LLY)?
• Negative Sentiment: Sell‑side/independent skepticism and downgrade: a Seeking Alpha piece flagged a rating downgrade and cautioned that the "one‑way ride" may end, adding downside pressure from sentiment shifts. Eli Lilly: The One-Way Ride Can't Last Forever (Rating Downgrade)
• Negative Sentiment: Near‑term investor worries about pricing, competition and recent share weakness since earnings have led to short‑term selling/volatility despite strong top‑line results and guidance. Lilly (LLY) Down 3.7% Since Last Earnings Report

Eli Lilly and Company Profile

Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.

Want to see what other hedge funds are holding LLY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Eli Lilly and Company (NYSE:LLY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.